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Skeletal musclee (HMB), a leucine catabolite, has been shown to prevent exercise-induced
protein degradation and muscle damage. We hypothesized that HMB would directly regulate muscle-cell
proliferation and differentiation and would attenuate apoptosis, the latter presumably underlying satellite-
cell depletion during muscle degradation or atrophy. Adding various concentrations of HMB to serum-
starved myoblasts induced cell proliferation and MyoD expression as well as the phosphorylation of MAPK/
ERK. HMB induced differentiation-speciﬁc markers, increased IGF-I mRNA levels and accelerated cell fusion.
Its inhibition of serum-starvation- or staurosporine-induced apoptosis was reﬂected by less apoptotic cells,
reduced BAX expression and increased levels of Bcl-2 and Bcl-X. Annexin V staining and ﬂow cytometry
analysis showed reduced staurosporine-induced apoptosis in human myoblasts in response to HMB. HMB
enhanced the association of the p85 subunit of PI3K with tyrosine-phosphorylated proteins. HMB elevated
Akt phosphorylation on Thr308 and Ser473 and this was inhibited by Wortmannin, suggesting that HMB acts
via Class I PI3K. Blocking of the PI3K/Akt pathway with speciﬁc inhibitors revealed its requirement in
mediating the promotive effects of HMB on muscle cell differentiation and fusion. These direct effects of HMB
on myoblast differentiation and survival resembling those of IGF-I, at least in culture, suggest its positive
inﬂuence in preventing muscle wasting.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
Muscle growth in postnatal vertebrates is a highly regulated
process in which muscle progenitor cells (satellite cells) proliferate
and differentiate to form multinucleated myotubes which will
mature into new muscle ﬁbers. In adults, the normally quiescent
satellite cells re-enter the myogenic program in response to
regenerative cues such as injury or exercise. This myogenic program
is governed, at least in part, by the muscle-speciﬁc basic helix–loop–
helix (bHLH) family of transcription factors [1,2]. Upon satellite cell
activation, the muscle-speciﬁc transcription factors are expressed in
a sequential pattern, with Myf5 and MyoD being expressed in the
proliferating progeny, followed by myogenin expression as the cells
enter differentiation [3–5]. Several signaling pathways have been
implicated in transducing growth factor effects on myoblast
proliferation, differentiation and survival. The mitogen-activated
protein kinase/extracellular signal-regulated protein kinase
(MAPK/ERK) pathway has been reported to inducing cell prolifera-
tion [6,7]. Conversely, the phosphoinositide 3′-kinase (PI3K)/Akt972 8 9489337.
ll rights reserved.pathway has been reported to be play a major role in inducing cell
differentiation and hypertrophy [8,9]. In addition, Akt has been
previously shown to be involved in cell survival via inhibition of pro-
apoptotic proteins [10,11] and activation of anti-apoptotic proteins [12].
Although the number of satellite cells decreases to less than 5% in
mature adult skeletal muscle, they are the primary mediators of
muscle regeneration throughout life, implying that they can be
continuously renewed while maintaining the ability to generate
differentiated progeny and new myoﬁbers [13–15]. Nevertheless, in
pathological conditions such as muscular dystrophies and cachexia, or
with age, there is a decline in the absolute number of satellite cells,
leading to muscle atrophy as well as a tremendous loss of myoﬁbrillar
proteins from the skeletal muscle and decreased protein synthesis
[16–18]. Several reports have demonstrated that apoptosis is one of
the main reasons for satellite cell depletion in over exercised or aged
animals after injury [19,20], or during degeneration-regeneration
cycles in myopathies [21,22].
β-hydroxy β-methylbutyrate (HMB), a metabolite of the essential
branched-chain amino acid leucine, is produced endogenously in
small amounts and is one of the latest dietary supplements for the
promotion of gains in strength and lean body mass when associated
with resistance training [23–27]. Other studies have shown that HMB
is more beneﬁcial in untrained individuals than in trained athletes
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pathological conditions, where it has been reported to reduce muscle
wasting associated with muscular dystrophies, trauma and cancer
cachexia [30,32,33]. In the mdx mouse model of Duchenne muscular
dystrophy, HMB alone or in combinationwith corticosteroids has been
shown to improve muscle function and to decrease retroperitoneal
fat-pad deposition [32]. Nevertheless, HMB's mode of action, in
general and in muscle in particular, is still controversial. HMB may
provide a source of cytosolic HMG-CoA for cholesterol synthesis,
allowing a larger supply of cholesterol for cell membrane synthesis
and therefore, maintenance of sarcolemmal integrity [34]. Other
reports have shown that HMB reduces cancer-induced muscle weight
loss via attenuation of the ubiquitin–proteasome proteolytic pathway
[33,35,36], suggesting that HMB functions predominantly as an anti-
catabolic, rather than anabolic compound. However, a recent studyFig. 1. Effect of HMB on labeled-thymidine incorporation into DNA in primary cultures of m
serum-starved for 40 h followed by addition of HMB at various concentrations for 17 h, after
replicates of three different experiments. (C) MyoD mRNA expression in response to variou
expression levels were evaluated by semi-quantitative RT-PCR analysis using 18S as an intern
Densitometry analyses for MyoD levels normalized to 18S (C, upper panel) or toα-tubulin (D
(E) and human (F) cultures was determined by Coulter counter after 24-hour incubation. Vhas shown that in cultured mouse cachectic myotubes, HMB
stimulates protein synthesis via the mTOR pathway, in addition to
attenuating the depression in protein synthesis induced by the
proteolysis-inducing factor [37]. In other cell systems, HMB has been
shown to have direct effects on cell proliferation and function [38,39].
Together, these reports led us to hypothesize that HMB, in addition to
protecting the muscle from degradation, also has a direct promotive
effect on myogenesis in adult muscle.
HMB has been shown to reduce muscle atrophy and increase
muscle hypertrophy by inhibiting muscle degradation [27]. However,
its direct effect on myogenic processes has never been studied. Here
we examined the effect of HMB on proliferation, differentiation and
fusion, as well as on the survival of muscle cell cultures derived from
non-mammalian and mammalian species. We show that it induces
myoblast proliferation and that the MAPK/ERK pathway is requiredyoblasts derived from 3-day-old chick (A) or in human CHQ myoblasts (B). Cells were
which [3H]thymidine was added for an additional 4 h. Results are means±s.e.m. of six
s concentrations of HMB in chicken myoblasts. Cells were treated as in (A) and mRNA
al control (lower panel). (D) MyoD protein expression in response to HMB in CHQ cells.
, upper panel) are presented as fold induction relative to control. Cell number in chicken
alues marked with different letters are signiﬁcantly different (Pb0.05).
Fig. 2. HMB increases markers of myogenic differentiation. One-day primary cultures of
chicken (A) or human (CHQ) myoblasts (B) were incubated in the absence or presence
of HMB at various concentrations for 24 h, and protein expression levels of myogenin,
MEF2 and MHC were analyzed by western blot. α-tubulin bands represent quantity of
protein loaded. (C) Dose-dependent induction of IGF-I mRNA levels in response to HMB
in chicken myoblasts. Cells were treated as in (A) and mRNA expression levels were
evaluated by semi-quantitative RT-PCR analysis using 18S as an internal control (lower
panel) followed by densitometry analysis for IGF-I normalized to 18S (upper panel).
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by cell starvation or staurosporine. The HMB-induced PI3K-dependent
Akt phosphorylation is required for HMB's promotive effect on
differentiation of myoblasts and myotube fusion. HMB triggers the
synthesis of (insulin-like growth factor-I (IGF-I) mRNA, suggesting
that the initial effects of HMB are boosted later on by IGF-I. Taken
together, these data suggest that HMB has a beneﬁcial effect on adult
skeletal muscle, both during normal growth and under stress
conditions.
2. Materials and methods
2.1. Materials
HMB was purchased from Metabolic Technologies Inc. Media and
sera were obtained from Invitrogen and Biological Industries,
respectively. Staurosporin was obtained from Sigma and UO126,
Wortmannin and Ly294002 were purchased from Calbiochem.
2.2. Cell preparation and maintenance
Human myoblasts (satellite cells) were isolated as described
previously [40] from the quadriceps muscle of a 5-d-old infant
(termed here CHQ) in accordance with the French legislation on
ethical rules and standards. Cells were grown in Ham's F10 medium
supplemented with 20% (v/v) fetal bovine serum (FBS). Chicken
myoblasts were isolated from the pectoralis muscle of 3-day-old
chicks as previously described [41], under the approval of the Animal
Welfare Committee of the Faculty of Agricultural, Food and Environ-
mental Quality Sciences at the Hebrew University of Jerusalem. Cells
were grown in DMEM containing 10% (v/v) horse serum. The mouse
myogenic cell line C2 [42] was grown in 20% FBS-containing DMEM.
All cells were maintained in 5% CO2. For cell proliferation assays, cells
were counted daily using a Coulter counter (Coulter Electronics).
2.3. Thymidine incorporation
DNA synthesis was assessed by [3H]thymidine incorporation as
previously described [41]. [3H]thymidine (New England Nuclear) was
added (2 μCi/well) for 4 h of incubation. Radioactivity in dissolved
precipitateswas counted using a Tri-Carb 1600CA scintillation counter
(Packard). Equal plating efﬁciency was veriﬁed by determining cell
numbers in parallel wells.
2.4. RNA preparation and RT-PCR
Total RNA was prepared using TRIzol™ Reagent (Invitrogen). Total
RNA (1 μg) was reverse-transcribed into cDNA using random primers
and SuperScript reverse transcriptase (Invitrogen). PCR was then
performed using Taq DNA polymerase (Fermentas) for the following
primers: 18S (F)—5′-CGA TGC TCT TAA CTGAGT GT-3′, 18S (R)—5′-TCA
GCT TTG CAA CCA TAC TC-3′ (419 bp), MyoD (F)—5′-CGT GAG CAG
GAG GAT GCA TA-3′, MyoD (R)—5′-GGG ACA TGT GGA GTT GTC TG-3′
(280 bp), IGF-I (F)—5′-GTA TGT GGA GAC AGA GGC TTC-3′, and IGF-I
(R)—5′-TTT GGC ATA TCA GTG TGG CGC-3′ (200 bp). Thirty-ﬁve cycles
(MyoD, IGF-I) or 20 cycles (18S) of ampliﬁcation were performed,
each consisting of 1 min at 94 °C, 1 min at 55 °C, and 1 min at 72 °C,
followed by a ﬁnal 10-minute extension at 72 °C. 18S was used as an
internal control to normalize the sample mRNA amounts. PCR
products were separated by electrophoresis and bands were visua-
lized by video camera (Dinco-Ranium).
2.5. Immunoprecipitation and western blot analysis
Cells were extracted with lysis buffer as described in [43] and
lysates were cleared by centrifugation. Equal amounts of proteinwereimmunoprecipitated withmonoclonal anti-phosphotyrosine antibody
(anti-pTyr, Upstate Biotechnology). The immunopellets were resus-
pended in SDS-PAGE sample buffer under reducing conditions and
subjected to electrophoresis and western blot analysis. Equal amounts
of protein were loaded and resolved by 7.5% (w/v) SDS-PAGE, then
transferred to nitrocellulose membranes (Biorad). After blocking, the
membranes were incubated with the following primary antibodies:
polyclonal anti-PI3K p85 pan (BD Biosciences), anti-phospho-MAPK/
ERK, anti-MAPK/ERK, anti-phospho-Akt and anti-Akt (Cell Signaling),
anti-MyoD, anti-MEF2 (Santa Cruz), monoclonal anti-myosin heavy
chain (MHC; MF20) (Hybridoma Bank), anti-Bcl-2, anti-BAX (BD
Pharmingen) and monoclonal anti-α-tubulin antibody (Oncogene).
2.6. Immunoﬂuorescence analysis
Cells were ﬁxed in 2% (w/v) paraformaldehyde for 15 min at room
temperature. After blocking in 5% (v/v) goat serum, cells were
incubated with the primary antibodies for 17 h at 4 °C, followed by
washes in PBS and incubationwith the secondary antibody for 30min.
The primary antibodies were: MF20 (1:10), rabbit anti-human Bcl-X
(1:50) and rabbit anti-human Bcl-2 (1:200) (Epitomics). Secondary
antibodies conjugated to either ﬂuorescein-isothiocyanate (FITC)
(Jackson Immuno Research) or Alexa-594 (Molecular Probes) were
758 R. Kornasio et al. / Biochimica et Biophysica Acta 1793 (2009) 755–763used for labeling. Nuclei were counterstained with Hoechst 33258
(Sigma).
2.7. Fusion assays
Fusion was analyzed by nuclear number assays as described by
Horsley et al. [44]. The number of nuclei in individual myotubes was
counted for 600–700 myotubes and these were grouped into
categories of either expressing two to four, or ﬁve or more nuclei.
The percentage of myotubes in each category was calculated.
2.8. Flow cytometry analysis
Apoptosis was induced by adding 0.5 μM staurosporine (Sigma) to
the proliferation medium for 16 h. Cells were collected, stained with
Annexin-V-FITC (BD Pharmingen) and propidium iodide (PI, Mole-
cular Probes), and analyzed by ﬂow cytometry using a FacsCalibur and
CellQuest software (Becton Dickinson). Percentage of apoptotic cells
was deﬁned by Annexin-V+PI− gated cells (adapted from Vermes et
al. [45]). Annexin-V is a Ca2+-dependent, phospholipid-binding
protein that has a high afﬁnity for phosphatidyl serine (PS) and
binds to cells with exposed PS [45].
2.9. Statistical analysis
Data were subjected to one-way ANOVA and to Student's t-test or
Tukey–Kramer test (for fusion analysis), using JMP® software [46].
3. Results
3.1. HMB promotes muscle cell proliferation
Chicken and human CHQ primary myoblast cell cultures, repre-
senting non-mammalian and mammalian species, were rendered
quiescent by placing them in serum-free medium for 40 or 48 h for
chick and human cells, respectively. We have previously shown that
this type of starvation does not induce myogenic differentiation and
that cells can be driven back into the cell cycle in the presence of
mitogens [42,47]. HMB was then added at various concentrations for
17 h, followed by thymidine labeling for an additional 4 h. In both cell
cultures, HMB increased the incorporation of thymidine into DNA by
more than 2.5-fold relative to untreated control cells (Fig. 1A, B). Its
effect was dose-dependent in chicken cells (Fig. 1A), whereas in the
CHQ cells, a sharp peak was observed at 50 μg/ml HMB (Fig. 1B)
(Pb0.05). The mRNA level of the muscle regulatory factor, MyoD,
which is upregulated in activated satellite cells, was elevated inFig. 3. Immunoﬂuorescence staining for MHC expression in muscle cells treated with HMB. M
or without various concentrations of HMB or with IGF-I and immunostained for MHC. Contro
7.5 ng/ml IGF-I (F). Bar, 20 μM for A, B, C, 40 μM for D, E, F.response to the addition of HMB in a dose-dependent manner in
chicken cells (Fig. 1C). In CHQ cells, the pattern of MyoD protein
accumulation in response to HMB paralleled that of thymidine
incorporation (Fig. 1D). Cell number increased dose-dependently
in response to HMB in both cell cultures after 24 h of incubation
(Fig. 1E, F). In CHQ cells, a signiﬁcant reduction in cell number was
observed at 200 μg/ml HMB (Fig. 1F).
The effect of HMB on cell proliferation was tested in myoblasts
derived from 3-day-old chicks, in which proliferation activity is
highest, and 7-day-old chicks when most of the proliferating
myoblasts have undergone differentiation and myoblast proliferation
and number have markedly declined [41]. As expected (Fig. 1A), in 3-
day-old chicks, HMB affected thymidine incorporation in a dose–
response manner. However, in 7-day-old chicks, cells were more
sensitive to HMB and a maximal effect was observed at 5 μg/ml HMB
(1000±120 vs. 2600±400 CPM for 0 and 5 μg/ml HMB, respectively,
Pb0.05). Thymidine incorporation declined at higher concentrations
of HMB (data not shown).
3.2. HMB promotes cell differentiation and fusion
Addition of various concentrations of HMB to serum-starved
chicken primary myoblasts for 24 h enhanced the protein levels of
the muscle differentiation factors myogenin and MEF2 (Fig. 2A) in a
dose-responsive manner, with the highest levels being observed at
100 μg/ml HMB. Similarly, MHC protein levels were induced in
these cells as well as in CHQ myoblasts in response to HMB
addition (Fig. 2A, B). The mRNA expression levels of IGF-I were dose-
dependently inducedbyHMBup to nearly twofold compared to control
untreated cells (Fig. 2C). HMB's potential role in the initial events of cell
fusion was analyzed as early as 24 h of incubation by immunoﬂuor-
escence analysis with an antibody against MHC in human CHQ cells, as
well as in themousemyogenic cell line, C2. In the case of C2,most of the
control cells that expressedMHCweremononuclear (84.3±0.03%, Fig.
3A). In the presence of higher concentrations of HMB, myotubes
containing two and more nuclei were observed (Fig. 3B, C). Quantita-
tion analysis of the number of nuclei in individual myotubes
revealed a signiﬁcant elevation in the percentage of myotubes con-
taining two to four nuclei in response to HMB (11.6 ± 0.03%, 33.4±
0.02%, 30.6±0.01% for 0, 20, 50 μg/ml HMB, respectively, Pb0.05).
The number of myotubes containing ﬁve or more nuclei was highest
in the presence of 50 μg/ml HMB (6.1±0.02% vs. 38.4±0.03% for 20
and 50 μg/ml HMB, respectively, Pb0.05).
Control CHQ cells expressed MHC but remained small and
mononuclear (96.7±0.03%, Fig. 3D), while in the presence of
100 μg/ml HMB (Fig. 3E) or 7.5 ng/ml IGF-I (Fig. 3F), larger MHC-ouse C2 cells (A–C) and human CHQ cells (D–F) were treated as described in Fig. 2 with
l, untreated cells (A, D), 20 μg/ml HMB (B), 50 μg/ml HMB (C), 100 μg/ml HMB (E) and
Fig. 4. HMB reduces muscle cell apoptosis. (A) C2 cells were serum-starved for 48 h, after which DMEMwas replaced with fresh medium in absence (a) or presence of 20 μg/ml (b)
and 50 μg/ml (c) HMB for an additional 24 h. DNA nuclei were stained with Hoechst dye. Note the fragmented/apoptotic nuclei (arrows) vs. the intact ones in control and HMB-
treated cells, respectively. (B) Apoptotic nuclei were counted and data are presented as a percentage of total nuclei. Values are expressed as means±s.e.m. of three independent
experiments in which more than 700 cells were examined. Values marked with different letters are signiﬁcantly different (Pb0.05). (C) Human CHQ myoblasts were induced to
apoptosis with staurosporine (STP; 0.5 μM) in the absence or presence of HMB. After 6 h cells were stained with FITC-conjugated Annexin-V and PI. Percentage of Annexin-V/PI-
stained cells was determined by ﬂow cytometry and this ﬁgure represents one of the HMB concentrations. The dot plot was divided into quadrants: necrotic cells (upper left), early
necrotic cells (upper right), living cells (lower left), and apoptotic cells (lower right). Graph demonstrates the number of apoptotic cells (lower right) in each treatment compared to
that of control cells treated with staurosporine alone (D). Values are expressed as means±s.e.m. of three independent experiments. ⁎Pb0.05 vs. control, untreated cells.
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containing two or more nuclei (2.9+0.01%, 9.9+0.01%, 10.4+0.02%
for 0, 100 μg/ml HMB and IGF-I, respectively, Pb0.05).
3.3. Effects of HMB on cell survival
One of the ways in which HMB may improve muscle growth and
more importantly, prevent muscle atrophy, is by enhancing muscle
cell survival and inhibiting apoptosis. To address this hypothesis,
apoptosis was induced by means of serum starvation or staurosporine
addition in C2 and CHQ cells, respectively. Previous studies have
shown the apoptotic effect of serum starvation in myoblasts [48,49].
C2 cells were serum-deprived for 48 h, after which HMB was or was
not added to the cells for an additional 24 h under the same
conditions. Cytochemical labeling of nuclei with Hoechst dye revealed
that HMB prevents the appearance of pycnotic nuclei (apoptotic
nuclei), the latter being observable only in the control serum-starved
cells (Fig. 4A). Quantitation analysis revealed that the percentage of
apoptosis, represented as the percent of pycnotic nuclei out of totalFig. 5. Expression levels of pro- and anti-apoptotic proteins are affected by HMB inmuscle cel
and cells were treated with or without HMB (200 μg/ml). Bcl-2 and Bcl-X were analyzed by
analysis for Bcl-2 and BAX proteins in serum-starved C2 cells. Cells were serum-starved for 48
α-tubulin bands represent quantity of protein loaded.nuclei (20.3±0.02% in control cells), was decreased byHMB in a dose-
responsive manner being almost threefold lower than controls at
50 μg/ml (Fig. 4B). Human CHQ cells were grown for 1 day in medium
containing 20% FBS after which HMB was added at various
concentrations for 10 h followed by the addition staurosporine
(0.5 μM) to induce apoptosis. Cells without the addition of
staurosporine served as controls. Cell death or apoptosis was
evaluated after 6-hour incubation by ﬂow-cytometry analysis using
PI staining and an antibody to Annexin-V. Annexin-V conjugated to
ﬂuorescein isothiocyanate (FITC) ﬂuorochrome retains its high afﬁnity
for PS and can therefore serve as a sensitive probe for the ﬂow-
cytometric detection of cell death. A typical ﬂow-cytometric plot of
CHQ cells labeled with Annexin and PI is shown in Fig. 4C. Four
different subpopulations of cells were detected: non-ﬂuorescent
viable cells (Fig. 4C, lower left panels), apoptotic cells labeled with
Annexin-FITC, but not with PI (Fig. 4C, lower right panels), early
necrotic cells labeled with Annexin-FITC and PI (Fig. 4C, upper right
panels), and cells labeled with PI but not with Annexin-FITC,
representing fully necrotic cells (Fig. 4C, upper left panels). In Fig.ls. Apoptosis was induced in CHQmyoblasts by staurosporine (STP) as described in Fig. 4
immunoﬂuorescence analysis and nuclei were stained with DAPI (A). (B) Western blot
h (zero time) then treated with 10 or 20 μg/ml HMB for an additional 24 h (24 h time).
Fig. 6. The MAPK/ERK pathway mediates the HMB promoting effect on muscle cell proliferation. Serum-starved C2 cells (A) or CHQ myoblasts (B) were stimulated with various
concentrations of HMB for 12 min. Cell lysates were resolved by SDS-PAGE and subjected to immunoblotting with anti-phospho-ERK1/2 antibody. The speciﬁcity of this induction is
demonstrated in C2 cells by UO126 (UO, 10 μM) treatment 30 min prior to HMB (20 μg/ml) addition. Parallel membranes were probed with anti-total ERK1/2 and anti-total Akt
antibodies. Upper panels: representativewestern blot analysis of MAPK/ERK phosphorylation. Lower panels: bands were quantiﬁed by densitometry relative to total MAPK/ERK and
results are means±s.e.m. of three independent experiments. Data with different letters differ signiﬁcantly (Pb0.05). Thymidine incorporation into DNA (D) and cell numbers (E) of
C2 cells were tested in the presence of 100 μg/ml HMB without or with 10 μM UO126 (+UO). Cells were treated as described in Fig. 1. Results are means±s.e.m. of six replicates of
three different experiments. Data with different letters differ signiﬁcantly (Pb0.001).
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concentrations of HMB was normalized to that of cells treated with
staurosporine alone (0) representing 100% (calculations included cells
that were found in the lower right panels). The percentage of
apoptosis was reduced by HMB in a dose-dependent manner, by
more than 30% at 200 μg/ml HMB; however, higher concentrations of
this compound reversed the effect, with the percentage returning to
control levels.
Next, we evaluated the expression levels of the Bcl-family
members which play a role in the immediate events of the apoptotic
response. CHQ cells were either treated or not treated with 200 μg/ml
HMB for 24 h, after which the medium was replaced with fresh
medium containing HMB (200 μg/ml) in a similar manner for an
additional 4 h, followed by the addition of staurosporine (0.5 μM) to
all plates to induce apoptosis. After 4 h of incubation with
staurosporine, cells were subjected to immunoﬂuorescence analysis
for Bcl-2 and Bcl-X. Both proteins were widely expressed in cells
incubated in the presence of staurosporine and HMB, whereas their
expression was low in the presence of staurosporine alone (Fig. 5A).
Quantitative analysis of two independent experiments revealed that
the percentage of cells expressing Bcl-2 or Bcl-X out of the total
number of cells increased from 22 to 49% and from 42.9 to 77.9%,
respectively, in the presence of HMB. A similar trend was observed in
serum-starved C2 cells: whereas Bcl-2 protein levels declined in the
untreated cells from 48 to 72 h of serum deprivation, 20 μg/ml HMBprevented this decline (Fig. 5B, compare time zero and 24 h). A lower
level of HMB had no effect on Bcl-2 levels. Conversely, the level of BAX,
an apoptosis-promoting molecule, was lower in the HMB-treated cells
compared to controls (Fig. 5B).
3.4. The MAPK/ERK and PI3K/Akt signaling pathways are induced
by HMB
In view of our results, we sought to determine whether HMB
induces signaling pathways such as those of MAPK/ERK and PI3K/Akt.
Serum-starved cells were incubated with various concentrations of
HMB for 12 min followed by western blot analysis for phosphorylated
and total MAPK/ERK proteins. MAPK/ERK phosphorylation was dose-
dependently induced in the chicken (Fig. 6A) and C2 cells (Fig. 6B) and
this phosphorylation was abolished in the presence of a MEK-speciﬁc
inhibitor UO126 (Fig. 6B). Similarly in CHQ cells, MAPK/ERK
phosphorylation was induced by increasing concentrations of HMB,
peaking at 50 μg/ml (Fig. 6C). To test whether the ERK/MAPK
pathway mediates HMB's effects on muscle cell proliferation, serum-
starved C2 cell were treated with 100 μg/ml HMB with or without
UO126 that was added 30 min prior to HMB addition. Thymidine
incorporation into DNA (Fig. 6D) and number of cells (Fig. 6E) were
evaluated after 17 and 24 h, respectively. In both cases, addition of
UO126 to HMB-treated cells abolished the promoting effect of HMB on
cell proliferation.
Fig. 7. The PI3K/Akt pathway is induced by HMB. Akt phosphorylation of serum-starved C2 (A) and human myoblasts (B) in response to various concentrations of HMB for 12 min.
Akt phosphorylation was analyzed by western blot with an anti-phospho-Akt (Ser473) (S473P-Akt) antibody followed by densitometric analysis normalized to levels of α-tubulin.
Data with different letters differ signiﬁcantly (Pb0.05). (C) Analysis of Akt phosphorylation at amino acid residues Thr308 (T308P-Akt) and Ser473 in C2 cells in the presence of
various concentrations of HMB, with or without Wortmannin (100 nM) for 12 min. (D) A western blot analysis for MHC in C2 cells treated for 24 h with 100 μg/ml HMB without
(HMB) or with Ly294002 (25 μM, Ly). C, control non-treated cells. (E) Recruitment of p85α and p85β isoforms of PI3K to tyrosine-phosphorylated proteins (p-Tyr) in response to
HMB (20 μg/ml). Serum-starved C2 cells were harvested with lysis buffer and subjected to immunoprecipitation (IP) with anti-pTyr antibody. Immunoprecipitates were resolved by
7.5% SDS-PAGE and subjected to immunoblotting with anti-p85 pan antibody. Protein quantity is represented by western blot for total Akt in cell lysates.
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Ser473was upregulated after 12min of incubationwith HMB in a bell-
shaped manner, to approximately sixfold more than control levels at
20 μg/ml HMB (Fig. 7A). Akt phosphorylation was induced in CHQ
cells in a dose-dependent manner (Fig. 7B). HMB induced the
phosphorylation of Akt phosphorylation sites, Ser473 and Thr308,
both of which are required for full kinase activity (Fig. 7C) [50,51]. This
phosphorylation was completely abolished in the presence of the
speciﬁc PI3K inhibitor Wortmannin (100 ng/ml). To test whether Akt
phosphorylation is required for HMB's stimulatory effect on myoblast
differentiation and fusion initiation, C2 myoblasts or myotubes were
treated with 50 μg/ml HMB for 24 h with or without Ly294002, a
stable PI3K inhibitor, which was added 30 min prior to the HMB
addition. A western blot analysis for MHC revealed that Ly294002
addition prevented the HMB-induced MHC levels in C2 cells (Fig. 7D).
Quantitation analysis of the number of nuclei in individual myotubes
revealed that Ly29004 treatment prevents the elevation in the
percentage of myotubes containing two to four nuclei in response to
HMB (30.4±0.17% and 1.7±0.01% for 50 μg/ml HMB alone or with
Ly294002, respectively, Pb0.05), and more than 95% of the cells
remained in their mononuclear state.
To analyze whether HMB is involved in the activation of Class I
PI3K, C2 cells were treated with or without 20 μg/ml HMB for various
times and cell lysates were subjected to immunoprecipitation with
anti-pTyr antibody. Western blot analysis with anti-p85 pan antibody,
which reacts with all isoforms of endogenous p85, revealed that HMB
induces the association of both p85α and p85β isoforms with
tyrosine-phosphorylated proteins (Fig. 7E).
4. Discussion
HMB has been suggested to inﬂuence muscle strength via various
mechanisms, such as decreasing protein degradation [27] andattenuating the proteosome–ubiquitin degradation pathway [35,36]
on the one hand, and increasing protein synthesis [37] on the other. In
this study, we provide the ﬁrst report of HMB's positive inﬂuence on
muscle via the promotion of proliferation and differentiation, the
acceleration of fusion, and the reduction of apoptosis in adult
myoblast cultures.
Direct addition of HMB to primary cultures of chicken and human
muscle cells, revealed its ability to stimulate cell proliferation. In both
species, the expression levels of MyoD, a marker for activated satellite
cells [3–5], thymidine incorporation by DNA and cell numbers were
increased in response to HMB. This is in complete agreement with
previous reports describing the mitogenic effect of HMB in other cell
types [38,39]. Although our cells were derived from young chick and
human skeletal muscles, they were rendered quiescent in order to
mimic their state in adult skeletal muscle. Moreover, following HMB
treatment, we observed enhanced proliferation of chicken myoblasts
derived from older chicks, in which satellite cell activity was very low
[41,52]. Taken together, our ﬁndings suggest that, at least in culture,
HMB has the ability to drive quiescent adult myoblasts into the cell
cycle, thus acting as a mitogen in these cells, regardless of the animal's
age. The differential response of human and chicken cells to HMB
suggests this mitogen's species-speciﬁc effect.
In addition to its mitogenic effect, HMB promoted terminal
muscle-cell differentiation and fusion. HMB increased in a dose-
dependant manner the protein levels of myogenic regulatory factors,
MEF2 as well as of MHC, and accelerated the appearance of myotubes.
This was evident in myoblasts derived from both chick and human
primary cell cultures, as well as in the C2 mouse cell line. HMB's effect
on muscle cell differentiation has also been observed in in-vivo
studies: administration of HMB to chick embryos by in-ovo feeding
enhances the expression levels of myogenic regulatory factors
in muscles of posthatch chicks relative to untreated controls
(R. Kornasio, Z. Uni and O. Halevy, unpublished). The fact that HMB
762 R. Kornasio et al. / Biochimica et Biophysica Acta 1793 (2009) 755–763triggered increased expression of IGF-I mRNA in primary chick
myoblasts raises the possibility of its affecting myoblast differentia-
tion via locally expressed IGF-I induction; this would induce the
expression of interleukin-4 and interleukin-13 [53], thereby promot-
ing cell fusion. This muscle-produced isoform of IGF-I is known for its
induction of muscle cell differentiation and hypertrophy [54].
The ﬁnding that proliferation and differentiation are induced by
24-hour treatment with HMB has been reported for other factors, such
as Shh [47]. Our explanation for this phenomenon is that the 2-day
starvation of myoblasts causes their withdrawal from the cell cycle,
but in a reversible manner. At the same time, this starvation period
renders some of the cells more prone to differentiation cues (perhaps
the cells that initiated this process beforehand). This implies an
heterogeneous population of muscle cells, in particular in the case of
the primary ones. Previously, we reported that primary myoblasts
derived from chicks at various ages, differ in their capacity to
proliferate or differentiate [52,55] Because HMB stimulates both
processes, some cells will proliferate better, whereas others will start
to differentiate in response to this amino acid.
Apoptosis is considered to be one of the mechanisms involved in
satellite cell depletion in cases such as trauma and aging, or during
degeneration–regeneration cycles in myopathies [19–22], thereby
contributing to an impaired skeletal muscle regeneration response. In
this study, we demonstrate that HMB reduces staurosporine- or
starvation-induced apoptosis in cultured human myoblasts and
mouse C2 cells, respectively. The number of apoptotic cells was
reduced in the presence of HMB and these cells exhibited higher levels
of the anti-apoptotic proteins Bcl-2 and Bcl-X and lower levels of the
pro-apoptotic protein BAX. These proteins, all of which belong to the
Bcl-2 family, regulate apoptosis by controlling mitochondrial integ-
rity: the anti-apoptotic proteins sequester the pro-apoptotic ones,
thereby preventing permeabilization of the outer mitochondrial
membrane and subsequent activation of downstream caspases [56].
Taken together, the beneﬁcial effect of HMB on muscle strength and
function in cases of muscle injury or wastage in trauma or cachexia
[32–36,57] might be explained in part by its protection of satellite cells
from depletion by apoptosis.
The signaling pathways via which HMB, a leucine catabolite, exerts
its effects are not fully understood. In this study, we demonstrate for
the ﬁrst time the promotive effect of HMB on MAPK/ERK and Akt
phosphorylation and the requirement of these pathways to mediate
its effects, as demonstrated by employing speciﬁc inhibitors. Our
results suggest that the MAPK/ERK pathway mediates HMB's effects
on myoblast proliferation (Fig. 6D, E), in agreement with earlier
reports [6,7,47]. By blocking the PI3K/Akt pathway with speciﬁc
inhibitors, we demonstrate that this pathway is required in mediating
the promotive effects of HMB on both, muscle cell differentiation and
fusion acceleration. The crucial role of Akt in myogenic differentiation
and hypertrophy has been previously demonstrated [8,9]. Moreover,
Akt has been shown to phosphorylate pro-apoptotic proteins and to
activate Bcl-2 expression [10–12], thus preventing apoptosis.
Recently, HMB has been reported to induce protein synthesis in
C2C12 myotubes via the mTOR/p70S6k pathway [37], a feature that is
shared with leucine [58]. Recent studies have reported that a class III
PI3K, human vacuolar protein sorting-34 (hVps34), mediates the
amino acid activation of mammalian target of rapamycin (mTOR) and
its downstream molecules, which is distinct from the effect of insulin,
which acts through class I PI3K [59,60]; these ﬁndings led Drummond
and Rusmussen [61] to conclude that leucine acts via the class III and
not class I PI3K pathway. Yet, one study has demonstrated that leucine
phosphorylates class I PI3K although no effects on its downstream
target, Akt were observed [62]. Our ﬁndings indicate that HMB
transduces its signal via class I PI3K pathway: HMB enhances the
recruitment of p85, the regulatory subunit of class I PI3K, to tyrosine-
phosphorylated proteins and fully activates Akt by inducing phos-
phorylation on both, Thr307 and Ser473 [50,51]; this latter phosphor-ylation is inhibited by Wortmannin, a speciﬁc PI3K inhibitor. This
distinction may give an additional explanation to the suggestion of
HMB being more potent than leucine in preventing muscle degrada-
tion [35–37]. We cannot rule out the possibility that HMB transduces
its signal also via hVps34 and activates the mTOR/p70S6k pathway in
a manner similar to other amino acids. However, due to the notion
that other amino acids signal directly to mTOR independent of the Akt
signaling pathway [59–62], we believe that HMB acts predominantly
via the class I PI3K/Akt pathway rather than the class III PI3K pathway.
The effects of HMB, at least in culture, on myoblast proliferation
and differentiation, as well as on apoptosis in adults, resemble those of
IGF-I. IGF-I has been reported to prevent muscle atrophy and wastage
[63], ameliorate muscle mass and force generation, and reduce
contraction-induced damage in muscles of dystrophic mdx mice
[64,65]. Although it is conceivable that HMB affects differentiation via
IGF-I, its effect is more likely to be direct. First, HMB's effect on cell
morphology and fusion was similar to that of IGF-I at the same time
point (Fig. 3F). Second, it had an immediate effect on Akt
phosphorylation (Fig. 7A, B) and on recruitment of p85 (Fig. 7E) but
not insulin receptor substrate-1 (IRS-1, data not shown) to Tyr-
phosphorylated proteins, suggesting the recruitment PI3K to some
other tyrosine-phosphorylated signaling complex. Because HMB
elevated IGF-I mRNA levels, we suggest that HMB has an immediate
direct effect on muscle cell differentiation and survival and that these
effect may be boosted later on via IGF-I secretion from these cells. Our
ﬁndings show a bell-shaped pattern for HMB's effects in all muscle
cells and in particular in humanmyoblasts. This resembles the activity
pattern of other growth factors, due to down-regulation and
internalization of their receptors. Although we do not know of any
speciﬁc receptor for HMB, we speculate that the bell-shaped activity
pattern indicates the existence of one.
In myopathies, the leading cause of satellite cell apoptosis as well
as muscle deterioration is continuous degeneration–regeneration
cycles in the damaged muscles [22,23]. Therefore, we believe that
the promotive effects shown here of HMB on muscle cell proliferation
and fusion, as well as on cell survival, together with its previously
demonstrated anti-catabolic effects [33,35,36], justify this supplement
as a therapeutic strategy to prevent muscle loss in myopathies as well
as in aging, trauma and cancer cachexia.Acknowledgements
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